Phone worldwide: +49 2103 29 11711
Phone U.S.: +1 240 686 2222
Phone worldwide: +49 2103 29 11826
Phone U.S.: +1 240 686 7425
QIAGEN on the web
Annual General Meeting of Shareholders of QIAGEN N.V.
Second Quarter 2021 Results
Third Quarter 2021 Results
Fourth Quarter 2021 Results (provisional)
Our name together with our logo is registered as a trademark in the United States and a number of other countries: QIAGEN®.
For a complete list of QIAGEN’s trademarks and disclaimers, please refer to QIAGEN’s webpage under www.QIAGEN.com/trademarks_disclaimers.aspx.
As of February 2021, QIAGEN molecular diagnostics products included 24 FDA (PMA-approved or 510 (k)-cleared) products, 18 clinical sample concentrator products (14 kits and 4 instruments) 60 EU CE IVD assays, 17 EU CE IVD sample preparation products, 18 EU CE IVD instruments for sample purification or detection, 34 China CFDA IVD assays/sample preparations and 9 China CFDA IVD instruments.
This Annual Report may also contain trade names or trademarks of companies other than QIAGEN.
© 2021 QIAGEN, all rights reserved.
This document contains detailed financial information about QIAGEN prepared under generally accepted accounting standards in the U.S. (U.S. GAAP) and included in our Form 20-F annual report filed with the U.S. Securities and Exchange Commission. QIAGEN also publishes an Annual Report under IFRS accounting standards, which is available on our website at www.QIAGEN.com.